Adma Biologics
ADMA9.9502.37% ( +0.230 )
Adma Biologics (ADMA)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficienci...
- Open
- 9.630
- High
- 10.030
- Low
- 9.620
- Prev. Close
- 9.720
- Volume
- 784.80K
- Turnover
- 7.74M
- Avg Price
- 9.859
- Bid/Ask Ratio
- 65.84%
- Amplitude
- 4.22%
- 52wk High
- 20.458
- Volume Ratio
- 1.16
- Turnover Ratio
- 0.36%
- 52wk Low
- 7.210
- Float Mkt Cap
- 2.19B
- Market CapUSD
- 2.23B
- P/ETTM
- 13.19
- P/EDynamic
- 13.40
- P/EStatic
- --
- EPSTTM
- 0.754
- EPSDynamic
- 0.742
- EPSStatic
- --
- BVPS
- 1.82
- P/B
- 5.46
- Circulating Supply
- 219.66M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 223.98M
- Min lot size
- 1
- Currency
- USD
Adma Biologics Analyst Rating
View moreForecast & Rating
Sep 10, 2026Price forecast
$17.0070.77%
Forecast & RatingBuy
4analysts
- Strong buy50.00%
- Buy25.00%
- Hold25.00%
- Sell0.00%
- Strong sell0.00%
News
- Weekly Review ·
Weekly Recap | Adma Biologics +3.62%, most brokers rate it buy
- Global Report ·
Supply Chain Reshoring Spurs Institutional Buying in Tech, Rail Stocks
- Global Report ·
Biotech's Innovation Surge Meets Plasma Giant's Governance Crisis
- Global Report ·
The Market's Algorithm Leftovers: A Bizarre Mix of Cash Machines and Oddballs
- Market Beat ·
WINTON GROUP Ltd Lowers Stock Holdings in ADMA Biologics Inc $ADMA
- Simplywall ·
ADMA Biologics (ADMA) Stock May Be Undervalued On Current Earnings
